Oxford Immunotec Global Plc (OXFD) 12.66 $OXFD
Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT
GlobeNewswire - Thu Feb 05, 6:01AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patients have been enrolled in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT.CMV and T-SPOT.PRT products.
OXFD: 12.66 (-0.53)
Oxford Immunotec Global PLC Announces Closing of Underwritten Offering of Ordinary Shares and Underwriters' Exercise of Option to Purchase Additional Shares
GlobeNewswire - Wed Feb 04, 3:06PM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"
, a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the closing of its underwritten offering of 4,893,616 ordinary shares at a public offering price of $11.75 per share, which includes the exercise in full by the underwriters of their option to purchase up to 638,297 additional ordinary shares. The offering generated gross proceeds of approximately $57.5 million with Oxford receiving net proceeds of approximately $53.7 million after deducting underwriting discounts and estimated offering expenses.
JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
Oxford Immunotec Global prices ordinary shares offering at USD11.75 per share
M2 - Mon Feb 02, 4:20AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) said on Friday that it has priced its underwritten offering of 4,255,319 ordinary shares at USD11.75 per share.
OXFD: 12.66 (-0.53)
Oxford Immunotec prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 7:29AM CST
OXFD: 12.66 (-0.53)
Oxford Immunotec Global PLC Announces Pricing of Underwritten Offering of Ordinary Shares
Thomson Reuters ONE - Fri Jan 30, 6:00AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company" , a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced its underwritten offering of 4,255,319 ordinary shares priced at $11.75 per share. The Company has granted the underwriters the option to purchase up to an additional 638,297 ordinary shares at the public offering price less the underwriting discount.
JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
Oxford Immunotec Global plans to launch an underwritten offering of ordinary stock
M2 - Fri Jan 30, 2:15AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) reported on Wednesday the start of an underwritten offering of its ordinary shares.
OXFD: 12.66 (-0.53)
Oxford Immunotec Global PLC Announces Proposed Underwritten Offering of Ordinary Shares
Thomson Reuters ONE - Wed Jan 28, 3:28PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company" , a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it has commenced an underwritten offering of its ordinary shares.
JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
Oxford Immunotec to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Tue Jan 27, 10:15AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Peter Wrighton-Smith Ph.D., Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the 2015 Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York, New York on Wednesday, February 11, 2015 at 2:40 pm ET.
OXFD: 12.66 (-0.53)
Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test
Thomson Reuters ONE - Tue Jan 06, 6:30AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that the company's T-SPOT(R).TB test has completed the re-registration process with the China Food and Drug Administration (CFDA). The registration became effective December 11, 2014 and lasts for five years.
OXFD: 12.66 (-0.53)
Oxford Immunotec to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Thomson Reuters ONE - Mon Dec 22, 12:00PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
James R. Tobin, Former CEO of Boston Scientific, Joins Oxford Immunotec Board of Directors
GlobeNewswire - Tue Dec 02, 9:50AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology, today announced the appointment of James R. Tobin to its Board of Directors.
BSX: 14.98 (+0.24), OXFD: 12.66 (-0.53)
Oxford Immunotec (OXFD) Looks Good: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:46AM CST
Oxford Immunotec (OXFD) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), OXFD: 12.66 (-0.53), ANGO: 18.78 (+0.18)
Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT
GlobeNewswire - Thu Feb 05, 6:01AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patients have been enrolled in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT.CMV and T-SPOT.PRT products.
OXFD: 12.66 (-0.53)
Oxford Immunotec Global PLC Announces Closing of Underwritten Offering of Ordinary Shares and Underwriters' Exercise of Option to Purchase Additional Shares
GlobeNewswire - Wed Feb 04, 3:06PM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"
, a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the closing of its underwritten offering of 4,893,616 ordinary shares at a public offering price of $11.75 per share, which includes the exercise in full by the underwriters of their option to purchase up to 638,297 additional ordinary shares. The offering generated gross proceeds of approximately $57.5 million with Oxford receiving net proceeds of approximately $53.7 million after deducting underwriting discounts and estimated offering expenses. JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
Oxford Immunotec Global prices ordinary shares offering at USD11.75 per share
M2 - Mon Feb 02, 4:20AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) said on Friday that it has priced its underwritten offering of 4,255,319 ordinary shares at USD11.75 per share.
OXFD: 12.66 (-0.53)
Oxford Immunotec prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 7:29AM CST
OXFD: 12.66 (-0.53)
Oxford Immunotec Global PLC Announces Pricing of Underwritten Offering of Ordinary Shares
Thomson Reuters ONE - Fri Jan 30, 6:00AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"
, a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced its underwritten offering of 4,255,319 ordinary shares priced at $11.75 per share. The Company has granted the underwriters the option to purchase up to an additional 638,297 ordinary shares at the public offering price less the underwriting discount. JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
Oxford Immunotec Global plans to launch an underwritten offering of ordinary stock
M2 - Fri Jan 30, 2:15AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) reported on Wednesday the start of an underwritten offering of its ordinary shares.
OXFD: 12.66 (-0.53)
Oxford Immunotec Global PLC Announces Proposed Underwritten Offering of Ordinary Shares
Thomson Reuters ONE - Wed Jan 28, 3:28PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"
, a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it has commenced an underwritten offering of its ordinary shares. JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
Oxford Immunotec to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Tue Jan 27, 10:15AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Peter Wrighton-Smith Ph.D., Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the 2015 Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York, New York on Wednesday, February 11, 2015 at 2:40 pm ET.
OXFD: 12.66 (-0.53)
Oxford Immunotec Announces Completion of Re-Registration in China for T-SPOT.TB Test
Thomson Reuters ONE - Tue Jan 06, 6:30AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that the company's T-SPOT(R).TB test has completed the re-registration process with the China Food and Drug Administration (CFDA). The registration became effective December 11, 2014 and lasts for five years.
OXFD: 12.66 (-0.53)
Oxford Immunotec to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Thomson Reuters ONE - Mon Dec 22, 12:00PM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
JPM: 59.67 (+0.10), OXFD: 12.66 (-0.53)
James R. Tobin, Former CEO of Boston Scientific, Joins Oxford Immunotec Board of Directors
GlobeNewswire - Tue Dec 02, 9:50AM CST
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology, today announced the appointment of James R. Tobin to its Board of Directors.
BSX: 14.98 (+0.24), OXFD: 12.66 (-0.53)
Oxford Immunotec (OXFD) Looks Good: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:46AM CST
Oxford Immunotec (OXFD) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ETRM: 1.21 (+0.06), FLDM: 37.93 (-0.47), OXFD: 12.66 (-0.53), ANGO: 18.78 (+0.18)
